Gaviscon mint chewable tablets, No. 12

Gaviscon mint chewable tablets, No. 12; 'Treatment of symptoms of gastroesophageal reflux, such as sour belching, heartburn, dyspepsia (indigestion, feeling of heaviness in the stomach), arising after eating, in patients with gastroesophageal reflux or during pregnancy ...

Inside, after thorough chewing.

Adults and children over 12 years old: 2-4 tablets after meals and before bedtime (up to 4 times a day). If, after 7 days of taking the drug, symptoms persist, you should consult a doctor to review therapy.

One chewable tablet [mint] contains:

active ingredients: sodium alginate 250 mg, sodium bicarbonate 133.5 mg, calcium carbonate 80 mg;

excipients: mannitol 255 mg, macrogol 20,000 30 mg, magnesium stearate 4 mg, aspartame 3.75 mg, copovidone 28 mg, acesulfame potassium 3.75 mg, mint flavor 12 mg.

Х hypersensitivity to any component of the drug;

Х phenylketonuria (see the section 'Special instructions');

Х children under 12 years of age.

Carefully:

If you have the following diseases or conditions, you should consult your doctor before using the drug: hypercalcemia, nephrocalcinosis and urolithiasis with the formation of calcium oxalate stones, congestive heart failure, and renal dysfunction. Application during pregnancy and breastfeeding: Clinical studies involving more than 500 pregnant women and the amount of data obtained in the post-registration period did not show congenital, fetal and neonatal toxicity of active substances. GavisconЃ can be used during pregnancy if clinically necessary and after consulting a doctor. GavisconЃ can be used during breastfeeding.

Pharmacology.

When taken orally, the active substances of GavisconЃ react quickly with the acidic contents of the stomach. This forms an alginate gel with a pH value close to neutral. The gel forms a protective barrier on the surface of the stomach contents, preventing gastroesophageal reflux from occurring for up to four hours. In severe cases of reflux (regurgitation), the gel enters the esophagus ahead of the rest of the gastric contents, where it reduces irritation of the esophageal mucosa. A decrease in irritation of the esophageal mucosa is felt 3-4 minutes after ingestion.

Pharmacokinetics:

The drug has no systemic bioavailability (not absorbed).

Special instructions:

Sodium The preparation contains sodium. In a dose of four tablets, the sodium content is 246 mg. This should be taken into account when it is necessary to adhere to a diet with limited salt content, for example, in some cases of congestive heart failure and with impaired renal function. Calcium Each dose of four tablets contains 320 mg of calcium carbonate. Care must be taken when treating patients with hypercalcemia, nephrocalcinosis and urolithiasis with the formation of calcium oxalate stones. Aspartame The drug contains aspartame, so it should not be used in patients with phenylketonuria. In addition, aspartame is a non-specific sweetener, so patients with diabetes can use this drug. The drug does not affect the ability to drive vehicles and mechanisms,as well as to engage in other potentially hazardous activities that require increased concentration of attention and speed of psychomotor reactions.

Side effect:

The assessment of the incidence of adverse reactions was made on the basis of the following criteria: very often (? 1/10), often (? 1/100, <1/10), infrequently (? 1/1000, <1/100), rarely (? 1 / 10000, <1/1000), very rare (<1/10000) and unspecified frequency (frequency cannot be calculated from available data). Immune system disorders: of unknown frequency - anaphylactic and anaphylactoid reactions, hypersensitivity reactions (urticaria). Disturbances from the respiratory system, chest and mediastinal organs: of unknown frequency - respiratory effects (bronchospasm). If any of the side effects indicated in the instructions are aggravated, or you notice other side effects that are not listed in the instructions, inform your doctor.

Overdose:

Symptoms: Abdominal bloating may occur. Treatment: symptomatic.

Interaction with other medicinal products:

Since calcium carbonate, which is part of the drug, exhibits antacid activity, at least 2 hours should pass between taking GavisconЃ and other drugs, especially when taken simultaneously with H2-histamine receptor blockers, antibiotics from the tetracycline group, digoxin, fluoroquinolone, iron salts, ketoconazole, neuroleptics, levothyroxine sodium, thyroid hormones, penicillamine, beta-blockers (atenolol, metoprolol, propranolol), glucocorticosteroids, chloroquine, bisphosphonates and estramustine.